Alnylam Pharmaceuticals Inc (ALNY)vsAlterity Therapeutics Ltd (ATHE)
ALNY
Alnylam Pharmaceuticals Inc
$301.98
-1.01%
HEALTHCARE · Cap: $39.47B
ATHE
Alterity Therapeutics Ltd
$4.02
-2.52%
HEALTHCARE · Cap: $88.31M
Smart Verdict
WallStSmart Research — data-driven comparison
Alnylam Pharmaceuticals Inc generates 64497% more annual revenue ($4.29B vs $6.64M). ALNY leads profitability with a 12.6% profit margin vs -219.9%. ALNY earns a higher WallStSmart Score of 65/100 (B-).
ALNY
Strong Buy65
out of 100
Grade: B-
ATHE
Avoid26
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+86.5%
Fair Value
$2381.02
Current Price
$301.98
$2079.04 discount
Intrinsic value data unavailable for ATHE.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 90 in profit
Revenue surging 96.4% year-over-year
Growing faster than its price suggests
Strong operational efficiency at 23.0%
Revenue surging 74.6% year-over-year
Conservative balance sheet, low leverage
Reasonable price relative to book value
Areas to Watch
0.0% earnings growth
Premium valuation, high expectations priced in
Trading at 37.5x book value
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -46.4% — below average capital efficiency
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : ALNY
The strongest argument for ALNY centers on Return on Equity, Revenue Growth, PEG Ratio. Revenue growth of 96.4% demonstrates continued momentum. PEG of 0.51 suggests the stock is reasonably priced for its growth.
Bull Case : ATHE
The strongest argument for ATHE centers on Revenue Growth, Debt/Equity, Price/Book. Revenue growth of 74.6% demonstrates continued momentum.
Bear Case : ALNY
The primary concerns for ALNY are EPS Growth, P/E Ratio, Price/Book. A P/E of 74.1x leaves little room for execution misses.
Bear Case : ATHE
The primary concerns for ATHE are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
ALNY profiles as a growth stock while ATHE is a hypergrowth play — different risk/reward profiles.
ALNY is growing revenue faster at 96.4% — sustainability is the question.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ALNY scores higher overall (65/100 vs 26/100) and 96.4% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Alnylam Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.
Alterity Therapeutics Ltd
HEALTHCARE · BIOTECHNOLOGY · USA
Alterity Therapeutics Limited researches and develops therapeutic drugs for the treatment of Parkinson's disease and other neurodegenerative diseases in Australia. The company is headquartered in Melbourne, Australia.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?